<p>Keybank National Association OH 在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在 Lantheus Holdings, Inc. (NASDAQ:LNTH - 免費報告) 的持倉削減了 63.7%。該基金在季度內出售了 327,696 股後，持有 187,026 股該醫療設備提供商的股票。截至最近的 SEC 文件，Keybank National Association OH 持有 Lantheus 0.28% 的股份，價值 9,593,000 美元。</p>
<ul>
<li>製藥行業拋售：RSI 指標顯示的 3 只股票你不應忽視</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也對該公司的持倉進行了調整。Wealth Enhancement Advisory Services LLC 在第二季度將其在 Lantheus 的持股增加了 77.8%。Wealth Enhancement Advisory Services LLC 目前持有 6,159 股該醫療設備提供商的股票，價值 495,000 美元，此前在上個季度又購買了 2,695 股。Janney Montgomery Scott LLC 在第二季度將其在 Lantheus 的持倉增加了 17.5%。Janney Montgomery Scott LLC 目前持有 31,388 股該醫療設備提供商的股票，價值 2,569,000 美元，此前在該期間又收購了 4,677 股。Truist Financial Corp 在第二季度將其在 Lantheus 的持倉增加了 6.1%。Truist Financial Corp 目前持有 6,696 股該醫療設備提供商的股票，價值 548,000 美元，此前在該期間又收購了 382 股。Empirical Financial Services LLC 以 Empirical Wealth Management 名義在第二季度將其在 Lantheus 的股份增加了 25.4%。Empirical Financial Services LLC 以 Empirical Wealth Management 名義目前持有 4,984 股該醫療設備提供商的股票，價值 408,000 美元，此前在上個季度又收購了 1,009 股。最後，Hardy Reed LLC 在第二季度將其在 Lantheus 的持倉增加了 97.3%。Hardy Reed LLC 目前持有 23,000 股該醫療設備提供商的股票，價值 1,882,000 美元，此前在該期間又購買了 11,340 股。99.06% 的股票目前由機構投資者持有。</p>
<h2>Lantheus 股票表現</h2>
<p>NASDAQ:LNTH 週一開盤價為 66.92 美元。該公司的速動比率為 2.49，流動比率為 2.67，債務與股本比率為 0.51。Lantheus Holdings, Inc. 的 12 個月最低價為 47.25 美元，最高價為 111.29 美元。該公司的 50 日移動平均線為 64.87 美元，200 日移動平均線為 59.77 美元。該公司的市值為 44.4 億美元，市盈率為 28.12，貝塔值為 -0.08。</p>
<ul>
<li>大規模突破：該 ETF 顯示小型股的巨大收益信號</li>
</ul>
<p>Lantheus (NASDAQ:LNTH - 獲取免費報告) 最近在 11 月 6 日發佈了其財報。該醫療設備提供商報告每股收益 (EPS) 為 1.27 美元，符合市場共識預期的 1.27 美元。Lantheus 的淨利潤率為 10.99%，股本回報率為 30.88%。該公司在本季度的收入為 3.8401 億美元，而分析師預期為 3.6342 億美元。在去年同期，該公司每股收益為 1.70 美元。Lantheus 的收入同比增長了 1.4%。Lantheus 將其 2025 財年的指導目標設定為每股收益 5.500-5.650。作為一個整體，賣方分析師預計 Lantheus Holdings, Inc. 本年度將發佈每股收益 6.01 美元。</p>
<h2>分析師評級變動</h2>
<p>一些分析師最近對 LNTH 股票發表了看法。瑞穗證券將 Lantheus 的目標價從 60.00 美元上調至 72.00 美元，並在 12 月 17 日的報告中給予該公司 “跑贏大盤” 的評級。Truist Financial 將 Lantheus 的目標價從 80.00 美元上調至 82.00 美元，並在 12 月 18 日的研究報告中給予該公司 “買入” 評級。高盛集團在 10 月 8 日的研究報告中將 Lantheus 的目標價設定為 77.00 美元，並給予該股票 “中性” 評級。最後，Weiss Ratings 在 1 月 6 日的報告中將 Lantheus 的評級從 “賣出 (d+)” 上調至 “持有 (c-)”。五位分析師對該股票給予了 “買入” 評級，三位分析師對該股票給予了 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 78.00 美元。</p>
<ul>
<li>這些醫療設備製造商是否準備好反彈？</li>
</ul>
<p><strong>閲讀我們對 LNTH 的最新分析</strong></p>
<h2>Lantheus 公司簡介</h2>
<p>(免費報告)</p>
<p>Lantheus Holdings, Inc. 是一家全球生命科學公司，專注於診斷成像劑和放射藥物的開發、生產和商業化。公司總部位於馬薩諸塞州北比勒裏卡，Lantheus 專注於增強心血管和腫瘤疾病的檢測和管理的產品。公司的產品組合包括超聲增強劑、正電子發射斷層掃描 (PET) 的分子成像示蹤劑，以及旨在將診斷和治療應用相結合的新興治療平台。</p>
<p>診斷成像部門包括超聲對比劑，如 DEFINITY® (脂質微球) 和 Sonazoid® (氟丁烷)，這些對比劑改善了心臟結構和血流的可視化。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Lantheus</li>
<li>特朗普剛剛簽署了它</li>
<li>黃金警報</li>
<li>什麼費用可以從資本利得税中扣除？</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>黃金市場崩潰的那一天</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxOVEg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxOVEg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Lantheus 嗎？</h2>
<p>在考慮 Lantheus 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Lantheus 並不在名單上。</p>
<p>雖然 Lantheus 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

標普全球醫療股指數 ETF - iShares

醫療業 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Keybank National Association OH 在第三季度減少了對 Lantheus Holdings, Inc. (NASDAQ:LNTH) 的持股比例，減持幅度為 63.7%，出售了 327,696 股。出售後，其持有 187,026 股，估值約為 960 萬美元。其他機構投資者也調整了他們的持倉，其中 Wealth Enhancement Advisory Services 和 Janney Montgomery Scott 的增持尤為顯著。Lantheus 報告第三季度每股收益為 1.27 美元，符合預期，營收為 3.8401 億美元。分析師對該股票的評級不一，普遍目標價為 78.00 美元</p>

<p>Keybank National Association OH cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 63.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,026 shares of the medical equipment provider's stock after selling 327,696 shares during the quarter. Keybank National Association OH owned 0.28% of Lantheus worth $9,593,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Keybank National Association OH 在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在 Lantheus Holdings, Inc. (NASDAQ:LNTH - 免費報告) 的持倉削減了 63.7%。該基金在季度內出售了 327,696 股後，持有 187,026 股該醫療設備提供商的股票。截至最近的 SEC 文件，Keybank National Association OH 持有 Lantheus 0.28% 的股份，價值 9,593,000 美元。</p>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥行業拋售：RSI 指標顯示的 3 只股票你不應忽視</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its holdings in Lantheus by 77.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,159 shares of the medical equipment provider's stock valued at $495,000 after buying an additional 2,695 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Lantheus by 17.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 31,388 shares of the medical equipment provider's stock valued at $2,569,000 after acquiring an additional 4,677 shares during the period. Truist Financial Corp increased its position in Lantheus by 6.1% in the 2nd quarter. Truist Financial Corp now owns 6,696 shares of the medical equipment provider's stock valued at $548,000 after acquiring an additional 382 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Lantheus by 25.4% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 4,984 shares of the medical equipment provider's stock valued at $408,000 after acquiring an additional 1,009 shares during the last quarter. Finally, Hardy Reed LLC lifted its holdings in shares of Lantheus by 97.3% during the second quarter. Hardy Reed LLC now owns 23,000 shares of the medical equipment provider's stock worth $1,882,000 after purchasing an additional 11,340 shares during the period. 99.06% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也對該公司的持倉進行了調整。Wealth Enhancement Advisory Services LLC 在第二季度將其在 Lantheus 的持股增加了 77.8%。Wealth Enhancement Advisory Services LLC 目前持有 6,159 股該醫療設備提供商的股票，價值 495,000 美元，此前在上個季度又購買了 2,695 股。Janney Montgomery Scott LLC 在第二季度將其在 Lantheus 的持倉增加了 17.5%。Janney Montgomery Scott LLC 目前持有 31,388 股該醫療設備提供商的股票，價值 2,569,000 美元，此前在該期間又收購了 4,677 股。Truist Financial Corp 在第二季度將其在 Lantheus 的持倉增加了 6.1%。Truist Financial Corp 目前持有 6,696 股該醫療設備提供商的股票，價值 548,000 美元，此前在該期間又收購了 382 股。Empirical Financial Services LLC 以 Empirical Wealth Management 名義在第二季度將其在 Lantheus 的股份增加了 25.4%。Empirical Financial Services LLC 以 Empirical Wealth Management 名義目前持有 4,984 股該醫療設備提供商的股票，價值 408,000 美元，此前在上個季度又收購了 1,009 股。最後，Hardy Reed LLC 在第二季度將其在 Lantheus 的持倉增加了 97.3%。Hardy Reed LLC 目前持有 23,000 股該醫療設備提供商的股票，價值 1,882,000 美元，此前在該期間又購買了 11,340 股。99.06% 的股票目前由機構投資者持有。</p>
</div><h2>Lantheus Stock Performance</h2>
<div class="lb-trans"><h2>Lantheus 股票表現</h2>
</div><p>NASDAQ:LNTH opened at $66.92 on Monday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a fifty day moving average of $64.87 and a 200-day moving average of $59.77. The firm has a market capitalization of $4.44 billion, a P/E ratio of 28.12 and a beta of -0.08.</p>
<div class="lb-trans"><p>NASDAQ:LNTH 週一開盤價為 66.92 美元。該公司的速動比率為 2.49，流動比率為 2.67，債務與股本比率為 0.51。Lantheus Holdings, Inc. 的 12 個月最低價為 47.25 美元，最高價為 111.29 美元。該公司的 50 日移動平均線為 64.87 美元，200 日移動平均線為 59.77 美元。該公司的市值為 44.4 億美元，市盈率為 28.12，貝塔值為 -0.08。</p>
</div><ul>
<li>Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>大規模突破：該 ETF 顯示小型股的巨大收益信號</li>
</ul>
</div><p>Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million for the quarter, compared to analyst estimates of $363.42 million. During the same period in the prior year, the firm earned $1.70 earnings per share. Lantheus's revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.</p>
<div class="lb-trans"><p>Lantheus (NASDAQ:LNTH - 獲取免費報告) 最近在 11 月 6 日發佈了其財報。該醫療設備提供商報告每股收益 (EPS) 為 1.27 美元，符合市場共識預期的 1.27 美元。Lantheus 的淨利潤率為 10.99%，股本回報率為 30.88%。該公司在本季度的收入為 3.8401 億美元，而分析師預期為 3.6342 億美元。在去年同期，該公司每股收益為 1.70 美元。Lantheus 的收入同比增長了 1.4%。Lantheus 將其 2025 財年的指導目標設定為每股收益 5.500-5.650。作為一個整體，賣方分析師預計 Lantheus Holdings, Inc. 本年度將發佈每股收益 6.01 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of analysts recently weighed in on LNTH shares. Mizuho increased their price objective on Lantheus from $60.00 to $72.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, December 17th. Truist Financial increased their price target on Lantheus from $80.00 to $82.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, December 18th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings upgraded Lantheus from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $78.00.</p>
<div class="lb-trans"><p>一些分析師最近對 LNTH 股票發表了看法。瑞穗證券將 Lantheus 的目標價從 60.00 美元上調至 72.00 美元，並在 12 月 17 日的報告中給予該公司 “跑贏大盤” 的評級。Truist Financial 將 Lantheus 的目標價從 80.00 美元上調至 82.00 美元，並在 12 月 18 日的研究報告中給予該公司 “買入” 評級。高盛集團在 10 月 8 日的研究報告中將 Lantheus 的目標價設定為 77.00 美元，並給予該股票 “中性” 評級。最後，Weiss Ratings 在 1 月 6 日的報告中將 Lantheus 的評級從 “賣出 (d+)” 上調至 “持有 (c-)”。五位分析師對該股票給予了 “買入” 評級，三位分析師對該股票給予了 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 78.00 美元。</p>
</div><ul>
<li>Are These Medical Device Makers Getting Ready To Rally?</li>
</ul>
<div class="lb-trans"><ul>
<li>這些醫療設備製造商是否準備好反彈？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on LNTH</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 LNTH 的最新分析</strong></p>
</div><h2>Lantheus Company Profile</h2>
<div class="lb-trans"><h2>Lantheus 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.</p>
<div class="lb-trans"><p>Lantheus Holdings, Inc. 是一家全球生命科學公司，專注於診斷成像劑和放射藥物的開發、生產和商業化。公司總部位於馬薩諸塞州北比勒裏卡，Lantheus 專注於增強心血管和腫瘤疾病的檢測和管理的產品。公司的產品組合包括超聲增強劑、正電子發射斷層掃描 (PET) 的分子成像示蹤劑，以及旨在將診斷和治療應用相結合的新興治療平台。</p>
</div><p>The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.</p>
<div class="lb-trans"><p>診斷成像部門包括超聲對比劑，如 DEFINITY® (脂質微球) 和 Sonazoid® (氟丁烷)，這些對比劑改善了心臟結構和血流的可視化。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Lantheus</li>
<li>Trump just signed it</li>
<li>GOLD ALERT</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Lantheus</li>
<li>特朗普剛剛簽署了它</li>
<li>黃金警報</li>
<li>什麼費用可以從資本利得税中扣除？</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>黃金市場崩潰的那一天</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE5USA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LNTH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lantheus Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Lantheus 嗎？</h2>
</div><p>Before you consider Lantheus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Lantheus 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Lantheus 並不在名單上。</p>
</div><p>While Lantheus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lantheus 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Keybank National Association OH Sells 327,696 Shares of Lantheus Holdings, Inc. $LNTH

Market Beat

醫療業 ETF - Vanguard

基因改革 ETF - ARK

紐交所高增長板生物技術指數 ETF - First Trust

美國制藥 ETF - iShares

Lantheus控股

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

Keybank National Association OH 出售了 327,696 股 Lantheus 控股公司的股票，股票代碼為$LNTH